LIFE Share Price | aTyr Pharma, Inc. Stock Analysis & Recommendation

Q: How big is aTyr Pharma, Inc.?

Market Cap: As of Jun 18, aTyr Pharma, Inc. has a market capitalization of 457.48 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, aTyr Pharma, Inc. reported net sales of 0.00 million and a net profit of -63.42 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 70.02 million and total assets of 98.05 million.

Q: What does aTyr Pharma, Inc. do?

Overview:aTyr Pharma, Inc. is a clinical-stage biotherapeutics company engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot:Most recent Net Sales: Not availableMost recent Net Profit: -15 Million (Quarterly Results - Mar 2025)Market-cap: USD 457.48 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.00Return on Equity: -84.50%Price to Book: 6.10Contact Details:Address: 3545 John Hopkins Ct Ste 250, SAN DIEGO CA: 92121-1115Tel: 1 858 7318389Fax: 1 858 7318394Website: https://www.atyrpharma.com/

Q: Is aTyr Pharma, Inc. overvalued or undervalued?

As of 14 March 2024, the valuation grade for aTyr Pharma, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its negative financial metrics, including a P/E ratio of NA due to losses, a Price to Book Value of 6.38, and an EV to EBITDA of -6.14. Additionally, the ROE stands at a concerning -84.50%, reflecting the company's struggles to generate returns for shareholders.In comparison with peers, aTyr Pharma's valuation metrics are notably weaker, with Chimerix, Inc. also categorized as does not qualify and showing a P/E of -8.6897, while DiaMedica Therapeutics, Inc. has a P/E of -5.6701. The overall peer comparison suggests that aTyr Pharma is not only underperforming against its immediate competitors but also lacks the financial stability to justify its current price. Despite a strong year-to-date return of 37.57%, the valuation metrics indicate that the stock is overvalued in the current market context.

Q: Is aTyr Pharma, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for aTyr Pharma, Inc. has changed from mildly bullish to bullish. However, the overall stance remains mixed due to conflicting indicators. The MACD shows a mildly bearish signal on the weekly timeframe but is bullish on the monthly. The RSI is bullish on the weekly but has no signal on the monthly. Moving averages indicate a mildly bullish trend on the daily, while the Bollinger Bands and Dow Theory are bearish on both weekly and monthly timeframes. In terms of performance, aTyr Pharma has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -70.99% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish but with weak strength due to the mixed signals from various indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

896.81 k

Shareholding (Dec 2025)

FII

8.31%

Held by 45 FIIs

DII

52.59%

Held by 46 DIIs

Promoter

0.39%

How big is aTyr Pharma, Inc.?

22-Jun-2025

As of Jun 18, aTyr Pharma, Inc. has a market capitalization of 457.48 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -63.42 million over the latest four quarters. The company reported shareholder's funds of 70.02 million and total assets of 98.05 million as of Dec 24.

View full answer

What does aTyr Pharma, Inc. do?

22-Jun-2025

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company focused on developing medicines for severe, rare diseases. It has a market cap of $457.48 million and reported a quarterly net loss of $15 million as of March 2025.

View full answer

Who are in the management team of aTyr Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of aTyr Pharma, Inc. includes John Clarke (Independent Chairman), Sanjay Shukla (President and CEO), and several independent directors: Timothy Coughlin, Jane Gross, Jeffrey Hatfield, Svetlana Lucas, and Paul Schimmel. They oversee the company's strategic direction and operations.

View full answer

Is aTyr Pharma, Inc. overvalued or undervalued?

25-Jun-2025

As of March 14, 2024, aTyr Pharma, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to negative financial metrics, including a P/E ratio of NA, a Price to Book Value of 6.38, an EV to EBITDA of -6.14, and a troubling ROE of -84.50%, indicating it underperforms compared to peers like Chimerix and DiaMedica.

View full answer

Is aTyr Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, aTyr Pharma, Inc. shows a bullish trend overall, despite mixed signals from indicators like MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -70.99%.

View full answer

Compare aTyr Pharma, Inc. with Similar Stocks

Chimerix, Inc.Aquestive Therapeutics, Inc.Achieve Life Sciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 88 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.11

Return on Equity

-93.63%

Price to Book

1.09

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-14 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

14.92%

6 Months

-16.43%

1 Year

-77.52%

2 Years

-57.57%

3 Years

-55.99%

4 Years

-86.16%

5 Years

-83.18%

aTyr Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-53.30%

EBIT Growth (5y)

-221.48%

EBIT to Interest (avg)

-47.36

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

78.42%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.09

EV to EBIT

0.01

EV to EBITDA

0.01

EV to Capital Employed

0.12

EV to Sales

-1.07

PEG Ratio

Dividend Yield

ROCE (Latest)

921.19%

ROE (Latest)

-93.63%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 21 Schemes (38.71%)

Foreign Institutions

Held by 45 Foreign Institutions (8.31%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -100.00% vs 0.00% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 45.53% vs -31.79% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.40",
          "val2": "-26.40",
          "chgp": "45.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.00",
          "val2": "-25.70",
          "chgp": "45.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-140,763.20%",
          "chgp": "14,076.32%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -50.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -15.78% vs -26.98% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-76.10",
          "val2": "-66.40",
          "chgp": "-14.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-74.10",
          "val2": "-64.00",
          "chgp": "-15.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-408,563.20%",
          "val2": "-288,995.70%",
          "chgp": "-11,956.75%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

0.20

-100.00%

Operating Profit (PBDIT) excl Other Income

-14.40

-26.40

45.45%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.00

-25.70

45.53%

Operating Profit Margin (Excl OI)

0.00%

-140,763.20%

14,076.32%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -100.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 45.53% vs -31.79% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.20

Operating Profit (PBDIT) excl Other Income

-76.10

-66.40

-14.61%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-74.10

-64.00

-15.78%

Operating Profit Margin (Excl OI)

-408,563.20%

-288,995.70%

-11,956.75%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -50.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -15.78% vs -26.98% in Dec 2024

All Annual Results

Company CV

About aTyr Pharma, Inc.

aTyr Pharma, Inc.

Pharmaceuticals & Biotechnology

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Company Coordinates

Company Details

3545 John Hopkins Ct Ste 250 , SAN DIEGO CA : 92121-1115

Tel: 1 858 7318389

https://www.atyrpharma.com/

Registrar Details